A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2017
At a glance
- Drugs GLWL 01 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Proof of concept
- Sponsors GLWL Research
- 10 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Status changed from suspended to discontinued because of Insufficient efficacy for this indication.
- 13 Jan 2017 Status changed from recruiting to suspended Between Study Parts.